Marijuana as a treatment for epilepsy and multiple sclerosis?
A “grass roots” movement
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Indian hemp, when pure and administered carefully, is one of the most valuable medicines we possess. —Queen Victoria’s personal physician1
The use of cannabis (marijuana) for medical purposes dates back almost five millennia. Western medicine publicly advocated marijuana’s medicinal properties in the mid-1800s; by the beginning of the 20th century, numerous articles in the medical literature recommended its use for a variety of disorders, including multiple neurologic conditions. The compound was available “over the counter” in pharmacies across the United States at that time.2 Cannabis remained on US formularies until 1941. It was removed only after Congress passed the Marijuana Tax Act of 1937, which severely hampered physicians from prescribing it.2 Currently in the United States, the drug is classified as a Schedule I drug under the Controlled Substances Act, thus criminalizing the use of this pharmaceutical agent.
In the United States, there have been numerous challenges to the laws that pertain to cannabis use for medical purposes. These challenges have resulted in 10 states allowing an exemption from criminal penalties for defined patients who possess and use medical marijuana under physician supervision. Alaska, Arizona, California, Colorado, Hawaii, Maine, Maryland, Nevada, Oregon, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Eye on Practice
Clinical perspectives on medical marijuana (cannabis) for neurologic disordersTerry D. Fife, Heidi Moawad, Constantine Moschonas et al.Neurology: Clinical Practice, August 06, 2015 -
Guideline Perspective
Medical marijuanaBetween a plant and a hard placeDavid S. Gloss, Edward H. Maa et al.Neurology: Clinical Practice, August 06, 2015 -
Research
Perspectives on marijuana use and effectivenessA survey of NARCOMS participantsStacey S. Cofield, Amber Salter, Tuula Tyry et al.Neurology: Clinical Practice, August 01, 2017 -
Special Article
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disordersReport of the Guideline Development Subcommittee of the American Academy of NeurologyBarbara S. Koppel, John C.M. Brust, Terry Fife et al.Neurology, April 28, 2014